Profilo
Camille Landis worked as the Vice President of Business Development at Relypsa, Inc. from 2015 to 2017.
Prior to that, she was the Senior Vice President of Corporate Development at Unity Biotechnology, Inc. and the Chief Business Officer at Eidos Therapeutics, Inc. Ms. Landis received an undergraduate degree from the University of St. Thomas and an MBA from the Haas School of Business.
Precedenti posizioni note di Camille Landis
| Società | Posizione | Fine |
|---|---|---|
| EIDOS THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2018 |
| RELYPSA INC | Corporate Officer/Principal | 01/08/2017 |
| UNITY BIOTECHNOLOGY, INC. | Corporate Officer/Principal | - |
Formazione di Camille Landis
| University of St. Thomas | Undergraduate Degree |
| Haas School of Business | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| UNITY BIOTECHNOLOGY, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
Eidos Therapeutics, Inc.
 Eidos Therapeutics, Inc. BiotechnologyHealth Technology Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Camille Landis
